1520010-86-9 Usage
Uses
Used in Pharmaceutical Industry:
Sofosbuvir Impurity is used as a reference standard for testing and quality control purposes in the pharmaceutical industry. It is utilized to check the purity of sofosbuvir and ensure that no harmful or undesired substances are present in the pharmaceutical product. This helps maintain the safety and efficacy of the drug for patient use.
Sofosbuvir Impurity is also used for assessing the stability and degradation products of sofosbuvir. By analyzing the presence and quantity of this impurity, pharmaceutical companies can guarantee the stability and quality of the drug, ensuring its safety and efficacy for patient use. This is crucial in maintaining the overall quality and reliability of the pharmaceutical product in the market.
Check Digit Verification of cas no
The CAS Registry Mumber 1520010-86-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,5,2,0,0,1 and 0 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1520010-86:
(9*1)+(8*5)+(7*2)+(6*0)+(5*0)+(4*1)+(3*0)+(2*8)+(1*6)=89
89 % 10 = 9
So 1520010-86-9 is a valid CAS Registry Number.
1520010-86-9Relevant academic research and scientific papers
Preparation method and application of thyroid hormone receptor beta subtype agonist derivative
-
Paragraph 0069; 0079-0083, (2020/04/17)
The invention relates to a thyroid hormone receptor beta subtype agonist derivative as shown in a general formula (I) which is described in the specification and a preparation method thereof. The invention also discloses application of the derivative in preparation of medicines for treating related diseases (related illnesses and diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and related illnesses and diseases such as alcoholic steatohepatitis, atherosclerosis, cardiovascular diseases and hypothyroidism).
LIVER PRODRUGS OF MITOCHONDRIAL PROTON IONOPHORES
-
, (2018/06/06)
The present invention provides novel liver-targeted prodrugs of mitochondrial proton ionophores. These compounds have utility in medicine including their use in treatment of diseases such as NASH and NAFLD.
